This product provides a CRISPR/Cas9-edited polyclonal knockout cell population targeting KPNA1 in the HeLa background, enabling loss-of-function studies of this critical nuclear transport receptor. The polyclonal population is generated by CRISPR/Cas9-mediated gene disruption, creating a heterogeneous pool of cells with impaired KPNA1 expression, which serves as a robust loss-of-function model for nucleocytoplasmic transport investigations.
HeLa is a widely used human cervical adenocarcinoma epithelial cell line, known for its high proliferation rate and efficient transfection. As a well-established model, HeLa cells have been instrumental in cancer research and studies of nuclear transport mechanisms, making them an ideal host for dissecting the role of KPNA1 in nucleocytoplasmic trafficking and cell cycle regulation.
KPNA1 encodes importin subunit alpha-1, which functions as an adaptor recognizing classical nuclear localization signals (NLS) on cargo proteins. It forms a heterodimer with importin beta (KPNB1) to mediate translocation through the nuclear pore complex. Key interacting partners include Ran GTPase, nucleoporins such as Nup50 and Nup153, and diverse cargo proteins including NF-??B p65, STAT1, p53, c-Myc, and Vpr. KPNA1 activity is regulated by RanGTP/GDP gradients and phosphorylation by kinases like CK2. Through transport of these cargoes, KPNA1 participates in NF-??B signaling, DNA damage response, cell cycle progression, and mitotic spindle assembly.
In HeLa cells, KPNA1 disruption impairs nuclear import of transcription factors essential for proliferation and survival, thereby modulating cell cycle dynamics and potentially altering migratory behavior. Given the dependence of cervical adenocarcinoma cells on nuclear transport for oncogenic signaling, this knockout model offers a valuable tool to dissect the role of KPNA1 in cancer cell biology and to evaluate nuclear transport inhibitors as potential therapeutics.
Researchers can use these polyclonal KPNA1 knockout HeLa cells in assays such as Western blotting of nuclear/cytoplasmic fractions to assess cargo localization, immunofluorescence to visualize protein redistribution, co-immunoprecipitation to probe importin interactions, NF-??B reporter assays to measure signaling output, and flow cytometry for cell cycle analysis. These applications support investigations into nucleocytoplasmic transport, cancer cell proliferation, viral nuclear import mechanisms, and drug target validation. For further details, please contact Ascent Research.
